VALUE PROPOSITION PRINT PAGE
Safety
Accuracy
Management Advantages

Safety
An independent study at prominent private hospitals showed that roughly 50% of all nurses had encountered four to five problems with air embolisms potentially being administered per month.

In addition, it was proved that nearly 35% of patients in the study encountered air in line, resulting in a potentially fatal air embolism.
(Ref. Fraser, N et al (Data on file Varori))

Nurses sometimes have to care for up to 50 patients at a time, or 50 IV sets at a time. This becomes a very tedious process and results in unsafe clinical practice for the patients.

There are currently very few known gravitational products available on the market that provides any protection for this potentially fatal problem.

The IV™flow’s built-in shut down mechanism promises to drastically reduce these eventualities, if not eliminate them completely.

Furthermore, as a result of the built-in shut down mechanism, the back flow of blood will be drastically reduced.

During clinical trials it was proven that the IV™flow reduces adverse events by 55% (statistically significant, p-value of 0.0069)
(Ref. SATRGAIT Trial, (Data on file Varori))

Back to top

Accuracy


Clinical studies where some of the best-known drip sets currently available on the market were compared to the IV™flow, showed the clear advantage of the IV™flow (in conjunction with an existing dial type IV set) with regard to consistent accuracy throughout the administration process.

During clinical trials it was proven that the mean deviation from the intended flow rate (where the IV™flow was incorporated) was just more than 5ml/hour compared to a mean deviation from the intended flow rate (where the IV™flow was NOT incorporated) of more than 30ml/hour (statistically significant, p-value of 0.00818)
(Ref. SATRGAIT Trial, (Data on file Varori))

The following table summarises the results of a recent clinical trial where the IV™flow was combined with a normal IV set (dial type) and compared to the same type of IV set without the IV™flow:

 

Combined average flow rate deviation

Combined mean flow rate deviation

 

start - finish

150min - finish

start - finish

150min - finish

Without IV™Flow

32.5%

34.9%

30%

31%

With IV™Flow

8.4%

5.3%

7%

3%

Results from clinical trials conducted
(Ref. Ker, A.M.E (Data on file Varori))


Results from clinical trials conducted Flow rate WITHOUT IV™flow


Flow rate WITH IV™flow

Back to top

Management Advantages

Further independent studies at prominent private hospitals proved that managing infusion sets is one of nurses’ and hospitals’ most time-consuming activities. It was proven that nurses spend up to 17% of their time managing infusion sets, including regular checks for flow, repriming when replacing vaculiters (fluid containers) and constantly readjusting the flow rates.

Nurses in private hospitals typically have to check up to 15 patients each and at some public hospitals, nurses are responsible for up to 50 patients each. This means that the checking and managing of IV sets becomes a very tedious and time-consuming activity. The IV™flow will eliminate most of these factors to the extent that the nurses will have more time available to care for the patients’ more pressing needs.

Stock control in hospitals is also a complicated and costly affair. Through the use of the IV™flow, stock control in terms of infusion sets will be simplified.

Observations of adverse events (AE) in a recent study (Ref Fraser, N et al Data on File (Varori)) showed that 53% of patients experienced an AE associated with infusion sets. Furthermore, it was proved that an incidence rate of at least 25% of infusion bags or bottles can be expected (at least one in four bags or bottles will result in an AE). It needs to be stated that these AEs were observed in high-service level private hospitals, implying that these AEs will definitely increase in lower service-level hospitals.

A total of 77% of AE manifestations were noted with either reverse blood flow and /or air-in-line occurring.

During clinical trials it was proven that the IV™flow reduces costs related to adverse events by 76% (statistically significant, p-value of 0.0069)
(Ref. SATRGAIT Trial, (Data on file Varori))

Back to top